PB 003
Alternative Names: PB-003; PB003 PureActivatorLatest Information Update: 30 Apr 2021
At a glance
- Originator Pure Biologics
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Natural killer cell stimulants; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 15 Apr 2021 Early research in Non-small cell lung cancer in Poland, prior to April 2021 (Parenteral) (Pure Biologics pipeline, April 2021)